Role of D1 and D2 Dopamine Receptors in the Mammalian Striatum: Electrophysiological Studies and Functional Implications
Pharmacological, biochemical, and anatomical studies have indicated that at least two receptors for dopamine (D1 and D2) are present in mammalian CNS (Creese et al., 1983; Stoof and Kebabian, 1984). D1 receptors are associated with the stimulation of adenylate cyclase, while D2 receptors mediate either the inhibition of adenylate cyclase or are unlinked with this enzyme. Although the pharmacological evidence in favor of this receptor heterogeneity is strong, the physiological and clinical implications of these receptor classifications are not fully clarified.
KeywordsDopamine Hull Catecholamine Haloperidol Bromocriptine
Unable to display preview. Download preview PDF.
- Arnt, J. and Hyttel, J., 1986, Behavioural differentiation between effects elicited at dopamine D1 and D2 receptors in rats, Clinical Neuropharmacol., 9(s6):17.Google Scholar
- Bernardi, G., Calabresi, P., Mercuri, N. and Stanzione, P., 1984, Dopamine decreases the amplitude of excitatory post-synaptic potentials in rat striatal neurons, in “The Basal Ganglia,” McKenzie, J.S. Kemm, R.E. and Wilcock, L.N., eds., Plenum Press, New York.Google Scholar
- Calabresi, P., Mercuri, N., Stefani, A., Stanzione, P. and Bernardi, G., 1986, Action of dopamine and of dopaminergic agonists on rat striatal neurons: an intracellular study “in vitro,” Neurosci. Lett., s26:316.Google Scholar
- Calabresi, P., Mercuri, N., Stanzione, P., Stefani, A., and Bernardi, G., 1987, Intracellular studies on the dopamine induced firing inhibition: evidence for D1 receptor involvement, Neurosci. in press.Google Scholar
- Hahn, R.A., Wardell, J.R., Saran, H.M., and Ridley, P.T., 1982, Characterization of the peripheral and central effects of SKF 82526, a novel dopaminergic receptor agonist, J. Pharmacol. Exp, Ther., 223:305.Google Scholar
- Waddington, J.L., Molloy, A.C, O’Boyle, K.M. and Moshurono, M., 1986, Motor consequences of D1 dopamine receptor stimulation and blockade, Clinical Neuropharmacol., 9(s6):20.Google Scholar